Gianluca Iacobellis 1, Silvia Gra-Menendez 1
Main idea: Dapagliflozin causes a rapid and significant EAT reduction that could be independent of weight loss.
Objective: Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor. It improves glucose control and induces moderate weight loss in patients with type 2 diabetes mellitus. It has been shown to reduce cardiovascular risk.
Methods: This hypothesis was tested in a 24-week, randomized, double-blind, placebo-controlled clinical trial in 100 patients with type 2 diabetes mellitus. Patients had BMI of 27 kg/m2 and hemoglobin A1c level of 8% on metformin monotherapy.
Results: In the dapagliflozin group, EAT decreased by 20% from baseline to 24 weeks. There was no statistically significant correlation between EAT and body weight changes.